PCRX

Pacira BioSciences Inc.

Price

$24.36

return (12m)

-3.29%

p/e

61.54

p/bv

1.34

DIVIDEND YIELD

0.00%

PCRX price

Pacira BioSciences

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PCRX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-4.21%

3 months

3.75%

1 year

-3.29%

2 years

74.25%

5 years

-56.82%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals PCRX

Valuation

P/E

61.54

Sector -4.38

Industry -4.38

P/BV

1.34

Sector 2.02

Industry 2.02

P/Revenue (PSR)

1.21

Sector -4.40

Industry -4.40

EV/EBITDA

37.59

Sector -263.09

Industry -263.09

EV/EBIT

178.97

Sector -702.90

Industry -702.90

P/EBITDA

7.76

Sector -4.39

Industry -4.39

P/EBIT

29.10

Sector -4.73

Industry -4.73

P/Total Assets

0.72

Sector 1.49

Industry 1.49

P/Net Current Assets

20.84

Sector -11.70

Industry -11.70

P/Working Capital

1.83

Sector -3.19

Industry -3.19

EPS

0.38

Sector -2.14

Industry -2.14

BVPS

17.23

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

79.21%

Sector 36.74%

Industry 36.74%

EBITDA Margin

14.01%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

2.94%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

2.51%

Sector -38.22%

Industry -38.22%

Net Profit Margins

1.96%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.15

Sector 0.03

Industry 0.03

Profitability

ROE

2.18%

Sector -65.14%

Industry -65.14%

ROA

1.18%

Sector -65.53%

Industry -65.53%

ROIC

5.22%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

5.04

Sector 2.90

Industry 2.90

Net Debt / EBITDA

4.16

Sector -6.07

Industry -6.07

Net Debt / EBIT

19.80

Sector -8.26

Industry -8.26

Net Debt / Equity

0.17

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.54

Sector -0.05

Industry -0.05

Equity/Assets

0.54

Sector 0.41

Industry 0.41

Liabilities/Assets

0.46

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

6.62%

Sector -

Industry -

5Y Earnings CAGR

-19.00%

Sector -

Industry -

FAIR VALUE OF Pacira BioSciences ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$24.36

Fair Value

$12.14

Upside Return potential.

-50.17%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals PCRX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PCRX Pacira BioSciences Inc.	$24.36	-2.13%	0.00%	61.54	1.34	2.18%	1.96%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PCRX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Pacira BioSciences

Pacira BioSciences Inc.

Average Investor10 user rating

4.0 (2 people)

United States

20 years

Founded: 2006

2011

Time since IPO - 15 years

624

Employees

Pacira BioSciences Inc. (United States) is listed on the Nasdaq and has a market capitalization of $900.90 million, with shareholders equity totaling $671.98 million.

The company employs approximately 624 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Pacira BioSciences Inc. reported $746.17 million in revenue, generating net income of $14.64 million.

Key financial metrics include a P/E ratio of 61.54, a price-to-book (P/B) ratio of 1.34, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PCRX.

Market cap

$900.90 million

Net worth

$671.98 million

$671,980,000.00

Assets

$1.24 billion

$1,243,980,000.00

Total Shares Outstanding

39.00 million

39,000,000

Average Daily Trading Volume

$582.71 Thousand

$582,706.00

Sector

Health Care

Industry

Biotechnology

PCRX

PCRX revenue and profits

Financial Results PCRX

DRAG THE FRAME TO SEE MORE DATA

PCRX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Pacira BioSciences (PCRX) today?

A cotação de Pacira BioSciences (PCRX) hoje está em US$ 24.36, com uma variação de -3.29% em relação ao último ano. A cotação de Pacira BioSciences (PCRX) iniciou o ano negociando na casa dos US$ 25.88 e hoje está em US$ 24.36. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Pacira BioSciences (PCRX) e dados de ações do Ibovespa e mercados internacionais.

Quando Pacira BioSciences (PCRX) paga dividendos?

Pacira BioSciences (PCRX) não distribuiu dividendos no último ano.

Is Pacira BioSciences (PCRX) a good investment?

Atualmente, Pacira BioSciences (PCRX) está cotada a US$ 24.36, com um P/L de 61.54, representando um desvio de 7,142% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -3.29 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -3.29%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Pacira BioSciences (PCRX) stock?

Investir em ações de Pacira BioSciences (PCRX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Pacira BioSciences (PCRX) yield today?

A rentabilidade de Pacira BioSciences (PCRX) foi de -4.21% no último mês, -3.29% no último ano e -56.82% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Pacira BioSciences (PCRX) hoje, o investimento total seria de US$ 2,436.00, com base na cotação atual de US$ 24.36.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 2,355.86
Em 5 anos: US$ 1,051.86
Em 10 anos: US$ 2,436.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PCRX

Pacira BioSciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PCRX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING PCRX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Pacira BioSciences

Pacira BioSciences Inc.

United States

20 years

2011

624

PROFIT X PRICE PCRX

Financial Results PCRX

PCRX cash flow

Asset, Revenue and Profit Growth - PCRX

PCRX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions